Friday, 16 October 2026European Markets

CRCAM ALP.PROV.CCI And HØLAND OG SETSKOG Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam alp.prov.cci (crap.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam alp.prov.cci (crap.pa) €80.10 5.15% 4.93%
høland og setskog (hspg.ol) kr139.00 4.55% 5.82%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam alp.prov.cci (crap.pa)

5.15% forward dividend yield and 4.93% return on equity

caisse régionale de crédit agricole mutuel alpes provence société coopérative provides banking products and services in france. the company offers bank accounts; cards; e-documents; savings products; pension and employee savings products; real estate and consumer credit loans; cash management, business creation finance, medium term credit, and leasing services. it also provides life, health, employee, professional vehicle, activity, car and two-wheeler, personal, home, leisure and daily, borrowers, and professional premises insurance products. in addition, the company offers agriculture banking products and services. the company serves individuals, associations, professionals, businesses, farmers, and communities. caisse régionale de crédit agricole mutuel alpes provence société cooperative was founded in 1885 and is based in aix-en-provence, france. caisse régionale de crédit agricole mutuel alpes provence société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam alp.prov.cci has a trailing twelve months eps of €19.25.

pe ratio

crcam alp.prov.cci has a trailing twelve months price to earnings ratio of 4.16. meaning, the purchaser of the share is investing €4.16 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.

more news about crcam alp.prov.cci.

2. høland og setskog (hspg.ol)

4.55% forward dividend yield and 5.82% return on equity

høland og setskog sparebank provides banking services for the retail and corporate markets in norway. it offers deposits and loans, as well as insurance products. the company was formerly known as holand sparebank and changed its name to høland og setskog sparebank in 2010. the company was founded in 1849 and is headquartered in bjørkelangen, norway.

earnings per share

as for profitability, høland og setskog has a trailing twelve months eps of kr9.73.

pe ratio

høland og setskog has a trailing twelve months price to earnings ratio of 14.29. meaning, the purchaser of the share is investing kr14.29 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.82%.

more news about høland og setskog.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com